Last reviewed · How we verify
Polypodium Leucotomos
Polypodium Leucotomos is a Small molecule drug developed by Henry Ford Health System. It is currently in Phase 2 development. Also known as: Helicocare, Heliocare.
Polypodium leucotomos is a supplement studied in clinical trials for conditions such as minimal erythema dose, aging, skin abnormalities, keratosis, and actinic keratosis. It is a component of a novel food supplement being investigated in a randomized double-blind trial for its effect on minimal erythema dose.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Polypodium Leucotomos |
|---|---|
| Also known as | Helicocare, Heliocare |
| Sponsor | Henry Ford Health System |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation (NA)
- The Effect of 8-week Dietary Intake of Novel Food Supplement on Minimal Erythema Dose (NA)
- Polypodium Leucotomos Extract for the Treatment of Melasma (NA)
- The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos (NA)
- Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers (PHASE2)
- A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors (PHASE1)
- Oral Polypodium Leucotomos for Melasma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polypodium Leucotomos CI brief — competitive landscape report
- Polypodium Leucotomos updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI
Frequently asked questions about Polypodium Leucotomos
What is Polypodium Leucotomos?
Who makes Polypodium Leucotomos?
Is Polypodium Leucotomos also known as anything else?
What development phase is Polypodium Leucotomos in?
Related
- Manufacturer: Henry Ford Health System — full pipeline
- Also known as: Helicocare, Heliocare
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing